These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12959631)

  • 1. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials.
    Agustí A; Bonet S; Arnau JM; Vidal X; Laporte JR
    Drug Saf; 2003; 26(12):895-908. PubMed ID: 12959631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
    Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
    Arch Intern Med; 2001 Jan; 161(2):165-71. PubMed ID: 11176729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
    Flather MD; Yusuf S; Køber L; Pfeffer M; Hall A; Murray G; Torp-Pedersen C; Ball S; Pogue J; Moyé L; Braunwald E
    Lancet; 2000 May; 355(9215):1575-81. PubMed ID: 10821360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
    Voors AA; de Kam PJ; van den Berg MP; Borghi C; Hochman JS; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):119-24. PubMed ID: 16025230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].
    Kardiologiia; 2008; 48(11):64-8. PubMed ID: 19076083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure.
    Kiowski W; Sütsch G; Dössegger L
    J Cardiovasc Pharmacol; 1996; 27 Suppl 2():S19-24. PubMed ID: 8723395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and adverse effects of ACE inhibitors in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis.
    Bœuf-Gibot S; Pereira B; Imbert J; Kerroum H; Menini T; Lafarge E; De Carvalho M; Vorilhon P; Boussageon R; Vaillant-Roussel H
    Eur J Clin Pharmacol; 2021 Mar; 77(3):321-329. PubMed ID: 33070218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction.
    Packard KA; Wurdeman RL; Arouni AJ
    Ann Pharmacother; 2002 Jun; 36(6):1058-67. PubMed ID: 12022909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H; Haas SJ; Eichhorn E; Ghali J; Gilbert E; Lechat P; Packer M; Roecker E; Verkenne P; Wedel H; Wikstrand J
    Eur Heart J; 2005 Oct; 26(20):2154-8. PubMed ID: 16014644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?
    Nelson KM; Yeager BF
    Ann Pharmacother; 1996 Sep; 30(9):986-93. PubMed ID: 8876861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.